Sanofi, once on FDA course for speedy approval, gains late expansion for Tzield
15th June 2026 Uncategorised 0Sanofi has gained an FDA expansion for its Type 1 diabetes treatment Tzield. The decision came nearly two months after an original target date under former FDA chief Marty Makary’s controversial Commissioner’s National Priority Voucher (CNPV) program.
More: Sanofi, once on FDA course for speedy approval, gains late expansion for Tzield
Source: fierce